skip to main content
Show Results with:

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Diem, Stefan et al.

Journal of immunotherapy: official journal of the Society for Biological Therapy. Volume 39:Issue 9 (2016, November); pp 379-382 -- Lippincott Williams & Wilkins

Online access

Searching Remote Databases, Please Wait